Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan

Glecaprevir and pibrentasvir are hepatitis C virus (HCV) pangenotypic inhibitors targeting NS3/4A protease and NS5A, respectively. This once-daily, fixed-dose combination regimen demonstrated high sustained virologic response 12 weeks postdosing (SVR(12)) rates in CERTAIN-1 and CERTAIN-2 studies in...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnan, Preethi, Schnell, Gretja, Tripathi, Rakesh, Beyer, Jill, Reisch, Thomas, Dekhtyar, Tatyana, Irvin, Michelle, Xie, Wangang, Fu, Bo, Burroughs, Margaret, Redman, Rebecca, Kumada, Hiromitsu, Chayama, Kazuaki, Collins, Christine, Pilot-Matias, Tami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786793/
https://www.ncbi.nlm.nih.gov/pubmed/29180522
http://dx.doi.org/10.1128/AAC.02217-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786793/
https://www.ncbi.nlm.nih.gov/pubmed/29180522
http://dx.doi.org/10.1128/AAC.02217-17

Ejemplares similares